Spain’s Pricing Gulf: differences between notified and achieved reimbursement prices

A report from Diariofarma, translated by Omakase Consulting, has found a significant and growing disparity between the notified and achieved reimbursement price of medications within Spain. As the achieved price is not publicly visible, this makes price comparison between countries much more difficult.

The report found that:

  • “2014 – 125 medications used the notified price, with an average difference of 15.1%
  • 2017 – 275 medications used the notified price, with an average difference of 21.5%
  • 2018 – 429 medications used the notified price, with an average difference of 33.1%
  • 2019 – 579 medications used the notified price, with an average difference of 43.1%”

There are concerns that this trend is increasing in both volume and incremental differences, which raises questions about its causes and the extent to which pharmaceutical companies can continue to absorb these pricing differences.

To read Omakase Consulting’s full translation of the report, which includes detailed statistical analysis and representative graphs, please click here.

Tagged with

Published 25. February 2019 in News, News Spain